{"@id":"https://bioecon.ru/technology/resistance-breaking-oncology-platform/","@type":"Technology","cluster":"therapeutics-platforms","formats":{"html":"https://en.bioecon.ru/technology/resistance-breaking-oncology-platform/","json":"https://en.bioecon.ru/api/v1/technology/resistance-breaking-oncology-platform/index.json"},"id":"resistance-breaking-oncology-platform","industries":["pharma","biomanufacturing"],"lang":"en","links":{"industries":["https://bioecon.ru/industries/pharma/","https://bioecon.ru/industries/biomanufacturing/"],"suppliers":["https://bioecon.ru/companies/novartis/","https://bioecon.ru/companies/isomorphic-labs/","https://bioecon.ru/companies/micropep-technologies/","https://bioecon.ru/companies/insilico-medicine/","https://bioecon.ru/companies/hlb-genex/","https://bioecon.ru/companies/genscript-probio-genscript/","https://bioecon.ru/companies/tsingke-biotechnology/","https://bioecon.ru/companies/altos-labs/","https://bioecon.ru/companies/gilead-sciences/","https://bioecon.ru/companies/string-bio/"]},"maturity":7,"name":"Resistance-Breaking Oncology Platform","regions":["ch","eu","us","cn"],"risk":"medium","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-11-22","entity":"Swiss Biotech Directory 2026","kind":"vendor","urls":["https://www.swissbiotech.org/directory/"]}],"stages":[{"n":1,"title":"Resistance mutation profiling"},{"n":2,"title":"Structure-based allosteric design"},{"n":3,"title":"Synthetic lethality screening"},{"n":4,"title":"Patient-derived xenograft validation"}],"summary":"A translational drug discovery engine combining circulating tumor DNA liquid biopsy sequencing with structure-guided allosteric chemistry to prospectively predict, synthesize, and validate next-generation therapeutics targeting secondary gatekeeper mutations and bypass signaling pathways.","url":"/technology/resistance-breaking-oncology-platform/","verified":"2026-11-22"}